Table 3.
DMTs used by the participants.
Drug name | Number (%) | Drug name | Number (%) |
---|---|---|---|
No drug | 26 (3.5) | Natalizumab | 28 (3.7) |
IFN beta-1a (IM) | 96 (12.7) | Rituximab | 229 (30.4) |
IFN beta-1a (SC) | 39 (5.2) | Ocrelizumab | 21 (2.8) |
IFN beta-1b | 17 (2.3) | Cyclophosphamide | 1 (0.1) |
Glatiramer acetate | 46 (6.1) | Mitoxantrone | 2 (0.3) |
Teriflunomide | 16 (2.1) | Azathioprine | 3 (0.4) |
Dimethyl fumarate | 99 (13.1) | Mycophenolate mofetil | 1 (0.1) |
Fingolimod | 97 (12.9) | Missing | 31 (4.3) |